GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Progen Co Ltd (XKRX:296160) » Definitions » Sale Of Business

Progen Co (XKRX:296160) Sale Of Business : ₩ Mil (TTM As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Progen Co Sale Of Business?

Progen Co's sale of business for the six months ended in Dec. 2024 was ₩4,312.5 Mil. It means Progen Co gained ₩4,312.5 Mil from selling business. Progen Co does not have enough years/quarters to calculate the sale of business for the trailing twelve months (TTM) ended in Dec. 2024.

Compared with last quarter (₩0.0 Mil in Dec. 2023 ), Progen Co gained more money from selling business in Dec. 2024 (₩4,312.5 Mil).


Progen Co Sale Of Business Historical Data

The historical data trend for Progen Co's Sale Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Progen Co Sale Of Business Chart

Progen Co Annual Data
Trend Dec23 Dec24
Sale Of Business
- 4,312.49

Progen Co Semi-Annual Data
Dec23 Dec24
Sale Of Business - 4,312.49

Progen Co Sale Of Business Calculation

The amount earned to sell business.



Progen Co Sale Of Business Related Terms

Thank you for viewing the detailed overview of Progen Co's Sale Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.


Progen Co Business Description

Traded in Other Exchanges
N/A
Address
172 Magokjungang-ro, 7th Floor, Bio Innovation Park, Gangseo-gu, Seoul, KOR
Progen Co Ltd is an R&D focused biopharmaceutical development venture. It is engaged in developing metabolic disease treatments, immune disease treatments, and immune anti cancer drugs using its immunology based drug development know how, and is focusing on developing inventive drugs through domestic and international open innovation.

Progen Co Headlines

No Headlines